SCHEMBL4128675

SCHEMBL4128675

O=C(O)Cc1ccc(NC2=NC(=O)C(=Cc3ccc(-c4cc(F)c(F)cc4F)cc3F)S2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 6/20 0.35
PDE4D Q08499 6/20 0.35
TDP1 Q9NUW8 3/20 0.33
MEN1 O00255 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
RECQL P46063 1/20 0.33
RAB9A P51151 1/20 0.33
HTT P42858 1/20 0.33
HPGD P15428 1/20 0.32
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31
CYP26A1 O43174 1/20 0.30
CYP26B1 Q9NR63 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128672 1.00 PDE4B (0.35) PDE4BPDE4DTDP1MEN1ALDH1A1
SCHEMBL4140928 0.77 PDE4B (0.41) PDE4BPDE4DTDP1MEN1MAPT
SCHEMBL4140926 0.77 PDE4B (0.41) PDE4BPDE4DTDP1MEN1MAPT
SCHEMBL4140435 0.77 PDE4B (0.42) PDE4BPDE4DTDP1MEN1KMT2A
SCHEMBL4140438 0.77 PDE4B (0.42) PDE4BPDE4DTDP1MEN1KMT2A
SCHEMBL4132695 0.74 KMT2A (0.46) PDE4BPDE4DTDP1MEN1ALDH1A1
SCHEMBL4132691 0.74 KMT2A (0.46) PDE4BPDE4DTDP1MEN1ALDH1A1
SCHEMBL4120791 0.72 ALOX5 (0.40) PDE4BPDE4DMEN1ALDH1A1MAPT
SCHEMBL4120795 0.72 ALOX5 (0.40) PDE4BPDE4DMEN1ALDH1A1MAPT
Acetic Acid SCHEMBL4137474 0.70 MEN1 (0.38) TDP1MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PDE4B 161/4885PDE4D 485/4885TDP1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.